Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Paper
  • Published:

Immortalized embryonic mouse fibroblasts lacking the RelA subunit of transcription factor NF-κB have a malignantly transformed phenotype

Abstract

The RelA transcription factor is part of dimeric complexes, most commonly either p50-RelA (NF-κB) heterodimers or RelA homodimers, that control a variety of cellular processes. Immortalized embryonic fibroblasts established from rela knockout mice have previously been shown to be more sensitive to apoptosis induced by tumor necrosis factor (TNF) than are control fibroblasts. In this report, we show that one line of rela−/− fibroblasts has additional phenotypes that distinguish them from control mouse fibroblasts. As compared to normal 3T3 cells, RelA-deficient fibroblasts have a spindled morphology, are less adherent to culture dishes, grow to a higher saturation density, and can form colonies in soft agar. These properties are consistent with a weakly transformed phenotype for rela−/− cells. Furthermore, RelA-deficient fibroblasts can form tumors in immunodeficient mice, but these tumors regress, probably because of the sensitivity of these cells to TNF. The ability of rela−/− fibroblasts to form colonies in soft agar can be reverted by re-expression of wild-type mouse RelA, but not by expression of RelA mutants that cannot form homodimers. There is no clear correlation between the absence of RelA and the levels of expression of other Rel/NF-κB family members or adhesion proteins (ICAM-1 and VCAM-1) whose genes have upstream κB sites. Taken together, these results suggest that RelA has tumor suppressing activity under some circumstances and that RelA complexes are involved in the control of a variety of cellular properties associated with oncogenesis.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6

Similar content being viewed by others

References

  • Bancroft GJ, Sheehan KC, Schreiber RD, Unanue ER . 1989 J. Immunol. 143: 127–130

  • Barkett M, Gilmore TD . 1999 Oncogene 18: 6910–6924

  • Beg AA, Baltimore D . 1996 Science 274: 782–784

  • Beg AA, Sha WC, Bronson RT, Ghosh S, Baltimore D . 1995 Nature 376: 167–170

  • Capobianco A, Gilmore TD . 1991 Oncogene 6: 2203–2210

  • Cogswell PC, Guttridge DC, Funkhouser WK, Baldwin Jr AS . 2000 Oncogene 19: 1123–1131

  • Doi TS, Marino MW, Takahashi T, Sakakaura T, Yoshida T, Old LS, Obata Y . 1999 Proc. Natl. Acad. Sci. USA 96: 2994–2999

  • Dorshkind K, Pollack SB, Bosma MJ, Phillips RA . 1985 J. Immunol. 134: 3798–3801

  • Finco TS, Westwick JK, Norris JL, Beg AA, Der CJ, Baldwin Jr AS . 1997 J. Biol. Chem. 272: 24113–24116

  • Ganchi PA, Sun S-C, Greene WC, Ballard DW . 1993 Mol. Cell. Biol. 13: 7826–7835

  • Gilmore TD . 1999 Oncogene 18: 6842–6844

  • Gilmore TD, Cormier C, Jean-Jacques J, Gapuzan M-E . 2001 Oncogene 20: 7098–7103

  • Gilmore TD, Gapuzan M-E, Kalaitzidis D, Starczynowski D . 2002 Cancer Lett. in press

  • Hannink M, Temin HM . 1990 Oncogene 5: 1843–1850

  • Iademarco MF, McQuillan JJ, Rosen GD, Dean DC . 1992 J. Biol. Chem. 267: 16323–16329

  • Jo H, Zhong R, Zhong H, McKinsey TA, Shao J, Beauchamp RD, Ballard DW, Liang P . 2000 Oncogene 19: 841–849

  • Morgenstern JP, Land H . 1990 Nucleic Acids Res. 18: 3587–3596

  • Pahl H . 1999 Oncogene 18: 6853–6866

  • Rayet B, Gélinas C . 1999 Oncogene 18: 6938–6947

  • Ricci A, Biroccio A, Trisciuoglio D, Cippitelli M, Zupi G, Bufalo DD . 2001 Br. J. Cancer 85: 1914–1921

  • Ryan KM, Ernst MK, Rice NR, Vousden KH . 2000 Nature 404: 892–897

  • Sif S, Gilmore TD . 1993 J. Virol. 67: 7612–7617

  • Trecca D, Guerrini L, Fracchiolla NS, Pomati M, Baldini L, Maiolo AT, Neri A . 1997 Oncogene 14: 791–799

  • van de Stolpe A, Caldenhoven E, Stade BG, Koenderman L, Raaijmakers JAM, Johnson JP, van der Saag PT . 1994 J. Biol. Chem. 269: 6185–6192

  • van Hogerlinden M, Rozell BL, Ährlund-Richter L, Toftgård R . 1999 Cancer Res. 59: 3299–3303

  • Wang CY, Cusack Jr JC, Liu R, Baldwin Jr AS . 1999 Nat. Med. 5: 412–417

  • Zong W-X, Bash J, Gélinas C . 1998 Cell Death Differ. 5: 963–972

Download references

Acknowledgements

We thank Mark Hannink, Alexander Hoffman, and David Baltimore for the rela−/− fibroblasts and helpful discussions, Youssef Jounaidi for the BOSC23 retrovirus-packaging cells, and Geoffrey Cooper for helpful discussions. We thank Nancy Rice for the anti-RelA antiserum. We thank Youssef Jounaidi and Beverly Keniston for help with mouse tumorigenicity assays. This work was supported by NIH grant CA47763 (TD Gilmore) and a small grant (to PV Yufit) from the Undergraduate Research Opportunities Program of Boston University. PV Yufit was partially supported by an NSF-REU grant and performed research as part of the Undergraduate Honors Program in Biochemistry and Molecular Biology at Boston University.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Thomas D Gilmore.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gapuzan, ME., Yufit, P. & Gilmore, T. Immortalized embryonic mouse fibroblasts lacking the RelA subunit of transcription factor NF-κB have a malignantly transformed phenotype. Oncogene 21, 2484–2492 (2002). https://doi.org/10.1038/sj.onc.1205333

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1205333

Keywords

This article is cited by

Search

Quick links